AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31439531
Drug: Topical antiseptic
RxNorm normalized name: BENZALKONIUM CHLORIDE 1.3 mg in 1 mL TOPICAL GEL [Germ Free Topical Antiseptic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antiseptic ointment + chemical cauterization
Trial: 31439531
Drug: Topical decongestant
RxNorm normalized name: Qlearquil Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical decongestant ointment + chemical cauterization
Trial: 31484191
Drug: Cynara scolymus
RxNorm normalized name: Cynara scolymus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cynara scolymus (500 mg twice daily)
Trial: 17713973
Drug: CP-481,715 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-481,715 (up to 3000 mg)
Trial: 17713973
Drug: CP-481,715 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-481,715 (300 mg) with ciclosporin
Trial: 17713973
Drug: CP-481,715 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-481,715 (300 mg) without ciclosporin
Trial: 17713973
Drug: CP-481,715 (escalating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-481,715 (escalating doses)
Trial: 11162416
Drug: budesonide/formoterol 160/4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: budesonide/formoterol 160/4.5 microg (1 inhalation)
Trial: 9783305
Drug: Symptom Score
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom Score (SS) assessment during treatment for acute lymphoblastic leukemia (ALL)
Trial: 9783305
Drug: Symptom Score
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom Score (SS) assessment during treatment for solid tumors receiving megatherapy with autologous bone marrow rescue
Trial: 9783305
Drug: Symptom Score
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom Score (SS) assessment during treatment for miscellaneous tumors
Trial: 2286469
Drug: Fosfomycin trometamol
RxNorm normalized name: trometamol
DrugBank: Tromethamine (DB03754)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosfomycin trometamol (3 g single dose)
Trial: 7872756
Drug: Cephalexin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin (0.5 g four times daily for 5 days)
Trial: 19330931
Drug: Lactobacillus GG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus GG (LGG) supplementation with standard triple therapy (amoxicillin 25 mg/kg twice per day, clarithromycin 10 mg/kg twice per day, omeprazole 0.5 mg/kg twice per day)
Trial: 19330931
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with standard triple therapy (amoxicillin 25 mg/kg twice per day, clarithromycin 10 mg/kg twice per day, omeprazole 0.5 mg/kg twice per day)
Trial: 2723127
Drug: Buprenorphine 0.3
RxNorm normalized name: buprenorphine 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 0.3 mg and saline
Trial: 2723127
Drug: Buprenorphine 0.3
RxNorm normalized name: buprenorphine 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 0.3 mg and naloxone 0.6 mg
Trial: 2723127
Drug: Buprenorphine 0.3
RxNorm normalized name: buprenorphine 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 0.3 mg and naloxone 0.45 mg
Trial: 2723127
Drug: Buprenorphine 0.3
RxNorm normalized name: buprenorphine 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 0.3 mg and naloxone 0.3 mg
Trial: 2723127
Drug: Buprenorphine 0.3
RxNorm normalized name: buprenorphine 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 0.3 mg and naloxone 0.15 mg
Trial: 22271702
Drug: Outpatient, oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient, oral amoxicillin plus ciprofloxacin
Trial: 22271702
Drug: Continued standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued standard treatment (intravenous antimicrobial therapy)
Trial: 20010073
Drug: Planned treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Planned treatment interruptions (PTI)
Trial: 17187491
Drug: Valproate combined
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproate combined with lithium or antipsychotic drugs
Trial: 17187491
Drug: Valproate (serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valproate (serum levels 75-99 microg/ml)
Trial: 2129317
Drug: oral nitrate
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral nitrate therapy
Trial: 7275281
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml of stored serum Biseko on the day of operation and the first postoperative day
Trial: 25791462
Drug: OCP combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCP combined with metformin (n=25)
Trial: 22717305
Drug: 5-hour preprocedural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-hour preprocedural intravenous hydration with isotonic saline (5h-HS)
Trial: 22717305
Drug: 20-hour preprocedural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-hour preprocedural intravenous hydration with isotonic saline (20h-HS)
Trial: 21129991
Drug: Biatrial reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biatrial reduction with reef‐imbricate suture technique and aggressive postoperative pharmacological therapy
Trial: 20027097
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg intravenously)
Trial: 17474814
Drug: Atomoxetine 40
RxNorm normalized name: atomoxetine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine 40 to 120 mg/day
Trial: 15191378
Drug: Gatifloxacin 400
RxNorm normalized name: gatifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin 400 mg once-daily for 5-10 days
Trial: 15191378
Drug: Co-amoxiclav 500
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav 500 mg + clavulanic acid 125 mg three-times-daily for 5-10 days
Trial: 9491502
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of a three-component acellular pertussis vaccine
Trial: 9491502
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of a five-component acellular pertussis vaccine
Trial: 9491502
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of a three-component acellular pertussis vaccine
Trial: 9491502
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of a five-component acellular pertussis vaccine
Trial: 8141107
Drug: Three-drug combination
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug combination (ODA)
Trial: 8141107
Drug: Two-drug combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-drug combination (OD)
Trial: 3320274
Drug: 100% oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% oxygen at 2 ATA for 90 minutes daily for 20 sessions
Trial: 3320274
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy with air using a simulated compression procedure
Trial: 30166311
Drug: Online cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online cognitive behaviour therapy for insomnia (CBT-I)
Trial: 24830830
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g of fish oil
Trial: 24830830
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g of fish oil plus a multivitamin
Trial: 24830830
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of fish oil plus a multivitamin
Trial: 24830830
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g fish oil multivitamin combination
Trial: 16148589
Drug: travoprost 0.004%/timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: travoprost 0.004%/timolol 0.5% fixed combination
Trial: 16148589
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of travoprost 0.004% and timolol 0.5%
Trial: 10049962
Drug: Once-daily dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dosing (ODD) of gentamicin at 4 mg/kg
Trial: 10049962
Drug: Twice-daily dosing
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily dosing (TDD) of gentamicin at 2.5 mg/kg every 12 hours
Trial: 7747292
Drug: New empirical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New empirical antibiotic regimen
Trial: 2040893
Drug: Agar methods
RxNorm normalized name: Agar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agar methods with 64 micrograms/ml breakpoint
Trial: 12780716
Drug: G. biloba
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G. biloba extract 40 mg three times daily
Trial: 8404553
Drug: Epinephrine-injection technique
RxNorm normalized name: epinephrine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine-injection technique
Trial: 27449641
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment plus dexamethasone (20 mg iv from day 1 to day 5, and 10 mg iv from day 6 to day 10)
Trial: 27449641
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment without dexamethasone
Trial: 20222964
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment feasibility as perceived by physicians
Trial: 20222964
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment feasibility as perceived by nurses
Trial: 20222964
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment feasibility as perceived by patients
Trial: 20222964
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment feasibility as perceived by relatives
Trial: 16152821
Drug: Qingxin Capsule
RxNorm normalized name: SILICON DIOXIDE 14 g in 100 g / .ALPHA.-TOCOPHEROL ACETATE 0.1 g in 100 g / SODIUM PYROPHOSPHATE 0.5 g in 100 g DENTAL PASTE, DENTIFRICE [Mastikis Qingxin Care Mastic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingxin Capsule (QC)
Trial: 16152821
Drug: AT1R AC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT1R AC plus CC gene type in EH patients
Trial: 16152821
Drug: AA gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AA gene type vs AA plus CC gene type
Trial: 16152821
Drug: Gene type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene type and hypotensive effect of treatments
Trial: 11008854
Drug: Two treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two treatments focused on improving interpersonal relationships with social skills training
Trial: 11008854
Drug: Two treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two treatments focused on improving interpersonal relationships without social skills training
Trial: 8880291
Drug: Clarithromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (250 mg twice a day for 5 days)
Trial: 8384658
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg once a day for 3 days)
Trial: 2050329
Drug: Torasemide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide (10 mg/day)
Trial: 2050329
Drug: Furosemide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (25 mg/day)
Trial: 6630285
Drug: Doxorubicin only
RxNorm normalized name: Doxorubicin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin only (60 mg/m2)
Trial: 6630285
Drug: Doxorubicin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60 mg/m2) with tocopherol (200 mg i.m. 6 h before treatment) and nifedipine (60 mg p.o. daily from 2 days before infusion)
Trial: 31805483
Drug: Desensitising cream
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desensitising cream containing NaF 9,000 ppm associated with 20% nanohydroxyapatite
Trial: 30658483
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (3200 IU daily for 3 months)
Trial: 30658483
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily for 3 months)
Trial: 17391816
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml dose of 7-valent pneumococcal conjugate vaccine
Trial: 17391816
Drug: 0.5 ml
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml dose of 23-valent pneumococcal polysaccharide vaccine
Trial: 10220541
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blocker treatment in high risk patients requiring diuretics
Trial: 8907622
Drug: Chloraminophene capsules
RxNorm normalized name: Chloraminophen
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloraminophene capsules
Trial: 8907622
Drug: Chloraminophene tablets
RxNorm normalized name: Chloraminophen
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloraminophene tablets
Trial: 30176835
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) as add-on to antidepressant treatment
Trial: 30176835
Drug: Placebo as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as add-on to antidepressant treatment
Trial: 27012420
Drug: Combined vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined vitamin E and selenium (200 µg/d L-selenomethionine)
Trial: 27012420
Drug: Selenium alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium alone (200 µg/d L-selenomethionine)
Trial: 20398269
Drug: Autologous platelet
RxNorm normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous platelet concentrate injections
Trial: 3203706
Drug: Concomitant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant treatment with 10 mg benazepril and 40 mg furosemide
Trial: 2407810
Drug: Fluorouracil (FUra)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil (FUra) administered intravenously at a dose of 370 mg/m2/d for 5 days
Trial: 2407810
Drug: Fluorouracil (FUra)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil (FUra) plus high-dose continuous infusion leucovorin calcium (500 mg/m2/d)
Trial: 971163
Drug: Mepiprazole hydrochloride
DrugBank: Mepiprazole (DB09197)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepiprazole hydrochloride (therapeutic preparation)
Trial: 21161651
Drug: Cystone® (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cystone® (2 tablets BID for 1 year)
Trial: 17597461
Drug: Levamisole (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (150 mg single dose as adjunct to quinine)
Trial: 17597461
Drug: Quinine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine treatment alone
Trial: 15234038
Drug: Number of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of perirectal seeds ≤2.0 mm from rectal wall
Trial: 15234038
Drug: Number of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of perirectal seeds 2‐4 mm from rectal wall
Trial: 11435528
Drug: Ca-HMB (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca-HMB (3 g/d)
Trial: 7914306
Drug: PRP-T vaccine
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP-T vaccine (Hib conjugate vaccine) given by separate injection according to an accelerated 2, 3, and 4 month schedule without a booster dose in the second year of life.
Trial: 7914306
Drug: Intention-to-treat analysis
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intention-to-treat analysis of PRP-T vaccine.
Trial: 7914306
Drug: PRP-T vaccine
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP-T vaccine (Hib conjugate vaccine) with follow-up until November 1, 1993.
Trial: 3056331
Drug: Thymopentin (TP‐5)
RxNorm normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin (TP‐5) 50 mg subcutaneously two hours preoperatively
Trial: 3056331
Drug: Thymopentin (TP‐5)
RxNorm normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin (TP‐5) 50 mg subcutaneously two hours preoperatively and 48 hours postoperatively
Trial: 27306255
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (5 ± 2 mg for 24 hours at 2 mL/h)
Trial: 25255724
Drug: Ulinastatin (UTI)
RxNorm normalized name: phenazopyridine hydrochloride Oral Tablet [UTI Relief]
DrugBank: Ulinastatin (DB12038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin (UTI) - intravenous infusion of 5000 IU/kg before anesthesia and at the start of surgery
Trial: 22117989
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg orally three times daily) plus fenofibrate (200 mg orally once daily)
Trial: 22117989
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg orally three times daily) plus placebo
Trial: 20183462
Drug: Herbal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal treatment for acute hepatitis
Trial: 16606971
Drug: Bortezomib (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (1.3 mg/m2) administered on days 1, 4, 8, and 11 of a 3-week cycle
Trial: 11316640
Drug: Salmeterol 42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 42 microg twice daily
Trial: 11316640
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide 36 microg four times daily
Trial: 8148464
Drug: Development of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Development of additional approaches to prevention and treatment
Trial: 3555597
Drug: 0.05% tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% tretinoin cream applied nightly after 5% 5-fluorouracil (5-FU) cream applied twice daily
Trial: 3555597
Drug: Control cream
RxNorm normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control cream applied nightly after 5% 5-fluorouracil (5-FU) cream applied twice daily
Trial: 28753486
Drug: Empagliflozin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (both doses)
Trial: 25664215
Drug: Milnacipran (100-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milnacipran (100-200 mg/d, dosed twice a day)
Trial: 16111420
Drug: Partial cochlear
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial cochlear implant insertion (8 electrodes)
Trial: 16111420
Drug: Full cochlear
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full cochlear implant insertion
Trial: 379955
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metronidazole and emetine
Trial: 379955
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (including antiamoebic drugs)
Trial: 27548998
Drug: Fractional carbon
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional carbon dioxide laser combined with betamethasone and salicylic acid solution
Trial: 27548998
Drug: Betamethasone and
RxNorm normalized name: betamethasone and mydriatics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone and salicylic acid solution
Trial: 27626365
Drug: Radical radiotherapy
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical radiotherapy with hormones
Trial: 27626365
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (other treatments)
Trial: 25383998
Drug: DVD presentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DVD presentation administered by a community mental health educator